Cytori Provides Business Update; Reports First Quarter Results
During the first quarter of 2012, Cytori Therapeutics (NASDAQ: CYTX) advanced its cardiac cell therapy product pipeline,…
During the first quarter of 2012, Cytori Therapeutics (NASDAQ: CYTX) advanced its cardiac cell therapy product pipeline,…
Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of RESTORE-2 trial results in the peer-reviewed Europ…
In 2011, Cytori Therapeutics (NASDAQ: CYTX) achieved important objectives towards validating Celution® technology in mul…
Cytori Therapeutics (NASDAQ: CYTX) today is reporting its third quarter 2011 business update and financial results.…
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that results from an economic analysis carried out by the UK NH…
Cytori Therapeutics, Inc. (NASDAQ:CYTX) reports that surgeons from North Tees and Hartlepool NHS Foundation Trust have p…
The US Patent and Trademark Office issued a new patent (US Patent No. 7,887,795; direct link to USPTO site - http://bit.…
Cytori (NASDAQ: CYTX) received approval from The Netherlands to initiate a pivotal European trial, named ADVANCE, to inv…
Cytori Therapeutics (Nasdaq:CYTX) reports second quarter and first half 2010 financial results. Further details, includi…
Cytori Therapeutics (NASDAQ: CYTX) received expanded European approval (CE Mark) for its Celution(R) System, a medical d…